REAl-world outcomes in CHronic lymphocytic leukemia patients receiving acalabrutinib in Romania - REACH

Study identifier:D8220R00055

ClinicalTrials.gov identifier:NCT06170671

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Observational, secondary data collection study to describe acalabrutinib treatment outcomes in chronic lymphocytic leukemia patients in real-life setting in Romania

Medical condition

Chronic Lymphocytic Leukemia

Phase

N/A

Healthy volunteers

No

Study drug

Non interventional study

Sex

All

Estimated Enrollment

250

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 13 Dec 2023
Estimated Primary Completion Date: 30 Sept 2028
Estimated Study Completion Date: 30 Sept 2028

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria